Overview

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Status:
RECRUITING
Trial end date:
2030-05-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Phase:
PHASE2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Glucocorticoids